DK3497103T3 - Pyridopyrimdinon-cdk2/4/6-inhibitorer - Google Patents

Pyridopyrimdinon-cdk2/4/6-inhibitorer Download PDF

Info

Publication number: DK3497103T3
Authority: DK; Denmark
Prior art keywords: pyridopyrimdinone; cdk2; inhibitors
Prior art date: 2016-08-15

Application number

DK17752493.1T

Other languages

English (en)

Inventor

Douglas Carl Behenna

Ping Chen

Kevin Daniel Freeman-Cook

Mehran Jalaie

Asako Nagata

Sajiv Krishnan Nair

Sacha Ninkovic

Martha Alicia Ornelas

Cynthia Louise Palmer

Eugene Yuanjin Rui

Robert Louis Hoffman

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-08-15

Filing date

2017-07-31

Publication date

2021-06-14

2017-07-31 Application filed by Pfizer filed Critical Pfizer

2021-06-14 Application granted granted Critical

2021-06-14 Publication of DK3497103T3 publication Critical patent/DK3497103T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

DK17752493.1T 2016-08-15 2017-07-31 Pyridopyrimdinon-cdk2/4/6-inhibitorer DK3497103T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201662371602P	2016-08-15	2016-08-15
US201762533347P	2017-07-17	2017-07-17
PCT/IB2017/054655 WO2018033815A1 (en)	2016-08-15	2017-07-31	Pyridopyrimdinone cdk2/4/6 inhibitors

Publications (1)

Publication Number	Publication Date
DK3497103T3 true DK3497103T3 (da)	2021-06-14

Family

ID=59631834

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK17752493.1T DK3497103T3 (da)	2016-08-15	2017-07-31	Pyridopyrimdinon-cdk2/4/6-inhibitorer

Country Status (41)

Country	Link
US (4)	US10233188B2 (da)
EP (1)	EP3497103B1 (da)
JP (1)	JP6563623B1 (da)
KR (1)	KR102236605B1 (da)
CN (2)	CN114394966A (da)
AU (1)	AU2017311645B2 (da)
BR (1)	BR112019002610A2 (da)
CA (1)	CA2975033C (da)
CL (1)	CL2019000368A1 (da)
CO (1)	CO2019001240A2 (da)
CR (1)	CR20190062A (da)
CU (1)	CU24522B1 (da)
CY (1)	CY1124206T1 (da)
DK (1)	DK3497103T3 (da)
DO (1)	DOP2019000030A (da)
EC (1)	ECSP19011216A (da)
ES (1)	ES2876411T3 (da)
GE (1)	GEP20217234B (da)
HR (1)	HRP20210871T1 (da)
HU (1)	HUE055978T2 (da)
IL (1)	IL264687B (da)
LT (1)	LT3497103T (da)
MA (1)	MA45920B1 (da)
MD (1)	MD3497103T2 (da)
MX (1)	MX2019001849A (da)
NI (1)	NI201900013A (da)
PE (1)	PE20190475A1 (da)
PH (1)	PH12019500329A1 (da)
PL (1)	PL3497103T3 (da)
PT (1)	PT3497103T (da)
RS (1)	RS61934B1 (da)
RU (1)	RU2726115C1 (da)
SG (1)	SG11201900799XA (da)
SI (1)	SI3497103T1 (da)
SV (1)	SV2019005836A (da)
TN (1)	TN2019000039A1 (da)
TW (1)	TWI663169B (da)
UA (1)	UA124804C2 (da)
UY (1)	UY37352A (da)
WO (1)	WO2018033815A1 (da)
ZA (1)	ZA201900716B (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA124804C2 (uk) *	2016-08-15	2021-11-24	Пфайзер Інк.	Піридопіримідинонові інгібітори cdk2/4/6
JP6952747B2 (ja) *	2018-09-18	2021-10-20	ファイザー・インク	がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ
JP2020097562A (ja) *	2018-09-25	2020-06-25	ファイザー・インク	ピリド［２，３−ｄ］ピリミジン−７（８ｈ）−オンの合成
US11066404B2 (en)	2018-10-11	2021-07-20	Incyte Corporation	Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
EP3903828A4 (en)	2018-12-21	2022-10-05	Daiichi Sankyo Company, Limited	COMBINATION OF AN ANTIBODY-DRUG CONJUGATE AND A KINASE INHIBITOR
CN113260617A (zh)	2019-01-17	2021-08-13	辉瑞公司	Cdk抑制剂的结晶形式
JP2022519772A (ja) *	2019-02-15	2022-03-24	インサイト・コーポレイション	サイクリン依存性キナーゼ２バイオマーカー及びその使用
US11384083B2 (en)	2019-02-15	2022-07-12	Incyte Corporation	Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
US11472791B2 (en)	2019-03-05	2022-10-18	Incyte Corporation	Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11919904B2 (en)	2019-03-29	2024-03-05	Incyte Corporation	Sulfonylamide compounds as CDK2 inhibitors
JP2022529930A (ja) *	2019-04-19	2022-06-27	ファイザー・インク	Ｐａｈを処置するための抗増殖薬
US11447494B2 (en)	2019-05-01	2022-09-20	Incyte Corporation	Tricyclic amine compounds as CDK2 inhibitors
WO2020223469A1 (en)	2019-05-01	2020-11-05	Incyte Corporation	N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
US20230053328A9 (en)	2019-05-24	2023-02-16	Pfizer Inc.	Combination therapies using cdk inhibitors
US20220241412A1 (en)	2019-05-24	2022-08-04	Pfizer Inc.	Combination therapies using cdk inhibitors
WO2021014360A1 (en)	2019-07-23	2021-01-28	Pfizer Inc.	Oral modified release dosage forms
JP2023509260A (ja)	2019-08-14	2023-03-08	インサイト・コーポレイション	Ｃｄｋ２阻害剤としてのイミダゾリルピリミジニルアミン化合物
AR120184A1 (es) *	2019-10-11	2022-02-02	Incyte Corp	Aminas bicíclicas como inhibidoras de la cdk2
CN114555600B (zh) *	2019-10-17	2024-03-01	辰欣药业股份有限公司	作为cdk2/4/6三重抑制剂的氨基嘧啶类化合物
US11702474B2 (en)	2019-12-17	2023-07-18	Pfizer Inc.	Antibodies specific for CD47, PD-L1, and uses thereof
JP2023515629A (ja) *	2020-02-28	2023-04-13	フォチョン・バイオサイエンシーズ・リミテッド	Ｃｄｋ２／４／６阻害剤としての化合物
WO2021176349A1 (en)	2020-03-05	2021-09-10	Pfizer Inc.	Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor
JP2021167301A (ja)	2020-04-08	2021-10-21	ファイザー・インク	Ｃｄｋ２阻害剤に対する腫瘍適応を抑制するためのｃｄｋ４／６およびｃｄｋ２阻害剤による同時処置
CN113773315A (zh) *	2020-06-10	2021-12-10	无锡佰翱得生物科学有限公司	细胞周期蛋白依赖性激酶2（cdk2）高选择性氘代抑制剂
CN115702155A (zh) *	2020-06-17	2023-02-14	微境生物医药科技(上海)有限公司	新型吡啶并[2,3-d]嘧啶-7(8H)-酮衍生物
WO2022015670A1 (en) *	2020-07-14	2022-01-20	Nikang Therapeutics, Inc.	Pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cyclin-dependent kinase 2 inhibitors
WO2022018667A1 (en)	2020-07-24	2022-01-27	Pfizer Inc.	Combination therapies using cdk2 and cdc25a inhibitors
CA3195063A1 (en)	2020-09-15	2022-03-24	Pfizer Inc.	Solid forms of a cdk4 inhibitor
WO2022113003A1 (en)	2020-11-27	2022-06-02	Rhizen Pharmaceuticals Ag	Cdk inhibitors
IL303661A (en) *	2020-12-22	2023-08-01	Nikang Therapeutics Inc	COMPOUNDS FOR BREAKING CYCLIN-DEPENDENT KINASE 2 THROUGH THE UBIQUITIN PROTEOSOME PATHWAY
WO2022149057A1 (en)	2021-01-05	2022-07-14	Rhizen Pharmaceuticals Ag	Cdk inhibitors
CN117858879A (zh) *	2021-01-15	2024-04-09	南京再明医药有限公司	Cdk2/4/6抑制剂及其制备方法和应用
WO2022258023A1 (zh) *	2021-06-09	2022-12-15	郑州同源康医药有限公司	用作cdk激酶抑制剂的化合物及其应用
WO2023281413A1 (en)	2021-07-09	2023-01-12	Pfizer Inc.	Methods and dosing regimens comprising pf-06873600 for the treatment of cancer
WO2023051302A1 (zh) *	2021-09-29	2023-04-06	中国医药研究开发中心有限公司	具有细胞周期蛋白依赖性激酶抑制活性的杂环化合物及其制备方法和医药用途
WO2023092104A1 (en) *	2021-11-18	2023-05-25	Onconova Therapeutics, Inc.	Methods and compositions for treating cancer
US11976073B2 (en)	2021-12-10	2024-05-07	Incyte Corporation	Bicyclic amines as CDK2 inhibitors
WO2023111810A1 (en)	2021-12-14	2023-06-22	Pfizer Inc.	Combination therapies and uses for treating cancer
WO2023141522A2 (en) *	2022-01-21	2023-07-27	Slap Pharmaceuticals Llc	Multicyclic compounds
WO2023249968A1 (en) *	2022-06-22	2023-12-28	Nikang Therapeutics, Inc.	Bifunctional compounds containing pyrido[2,3-djpyrimidin-7(8h)-one derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway
WO2024039903A2 (en) *	2022-08-19	2024-02-22	Kymera Therapeutics, Inc.	Cdk2 inhibitors and uses thereof
WO2024084364A1 (en)	2022-10-18	2024-04-25	Pfizer Inc.	Compounds for the treatment of cancer

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5376645A (en)	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko)	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en)	1995-09-15	1995-11-15	Pfizer Ltd	Pharmaceutical formulations
TW477787B (en)	1996-08-27	2002-03-01	Pfizer	Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
WO2000035298A1 (en)	1996-11-27	2000-06-22	Wm. Wrigley Jr. Company	Chewing gum containing medicament active agents
US6413971B1 (en)	1996-11-27	2002-07-02	Pfizer Inc	Fused bicyclic pyrimidine derivatives
US6498163B1 (en)	1997-02-05	2002-12-24	Warner-Lambert Company	Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
EP0964864B1 (en)	1997-02-05	2008-04-09	Warner-Lambert Company LLC	Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
GB9711643D0 (en)	1997-06-05	1997-07-30	Janssen Pharmaceutica Nv	Glass thermoplastic systems
SK10772002A3 (sk) *	2000-01-27	2004-01-08	Warner-Lambert Company	Pyridopyrimidinónové deriváty na liečbu neurodegeneratívnych ochorení
EE200200506A (et)	2000-03-06	2004-02-16	Warner-Lambert Company	5-alküülpürido[2,3-d]pürimidiinid kui türosiinkinaasi inhibiitorid
BRPI0207172B8 (pt)	2001-02-12	2021-05-25	Hoffmann La Roche	pirido-pirimidinas 6-substituída, sua composição e seu uso, bem como seu intermediário
KR20060111716A (ko) *	2002-01-22	2006-10-27	워너-램버트 캄파니 엘엘씨	2-(피리딘-2-일아미노)-피리도[2,3-ｄ]피리미딘-7-온
PA8577501A1 (es) *	2002-07-25	2004-02-07	Warner Lambert Co	Inhibidores de quinasas
US6951769B2 (en)	2003-06-04	2005-10-04	Texas Instruments Incorporated	Method for stripping sacrificial layer in MEMS assembly
PT1648889E (pt)	2003-07-11	2008-12-10	Warner Lambert Co	Sal isetionato de um inibidor selectivo da cdk4
WO2005082903A1 (en)	2004-02-18	2005-09-09	Warner-Lambert Company Llc	2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
US20060142312A1 (en) *	2004-12-23	2006-06-29	Pfizer Inc	C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
CA2624965A1 (en) *	2005-10-07	2007-04-19	Exelixis, Inc.	Pyridopyrimidinone inhibitors of pi3k.alpha.
PL1940839T3 (pl) *	2005-10-07	2013-12-31	Exelixis Inc	Pirydopirymidynonowe inhibitory PI3Kalfa
KR20090052385A (ko)	2006-09-08	2009-05-25	화이자 프로덕츠 인크.	2-（피리딘-2-일아미노）-피리도［2,3-ｄ］피리미딘-7-온의합성
AP2710A (en)	2006-09-15	2013-07-30	Pfizer Prod Inc	Pyrido (2, 3-D) Pyrimidinone compounds and their use as P13 inhibitors
EP1914234A1 (en) *	2006-10-16	2008-04-23	GPC Biotech Inc.	Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
DK2139484T3 (da) *	2007-04-10	2013-10-21	Exelixis Inc	Fremgangsmåder til behandling af cancer ved brug af pyridopyrimidinon-inhibitorer af PI3K-alfa
WO2009132980A1 (en) *	2008-04-29	2009-11-05	F. Hoffmann-La Roche Ag	Pyrimidinyl pyridone inhibitors of jnk.
WO2010022081A1 (en)	2008-08-19	2010-02-25	Array Biopharma Inc.	Triazolopyridine compounds as pim kinase inhibitors
CN102177161A (zh)	2008-10-22	2011-09-07	霍夫曼-拉罗奇有限公司	Jnk的嘧啶基吡啶酮抑制剂
MX2013011518A (es) *	2011-04-08	2014-06-04	Afraxis Holdings Inc	8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas para el tratamiento de desordenes del sistema nervioso y cancer.
CA2834282A1 (en) *	2011-04-29	2012-11-01	Exelixis, Inc.	Method of treating lymphoma using pyridopyrimidinone inhibitors of pi3k/mtor
TW201306842A (zh) *	2011-06-15	2013-02-16	Exelixis Inc	使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
AR088082A1 (es)	2011-10-13	2014-05-07	Lilly Co Eli	Moduladores selectivos del receptor androgeno
WO2013126656A1 (en) *	2012-02-23	2013-08-29	Abbvie Inc.	Pyridopyrimidinone inhibitors of kinases
KR101858913B1 (ko)	2013-02-21	2018-05-16	화이자 인코포레이티드	고체 형태의 선택적인 cdk4/6 억제제
TWI647220B (zh)	2013-03-15	2019-01-11	美商西建卡爾有限責任公司	雜芳基化合物及其用途
WO2015084936A1 (en) *	2013-12-04	2015-06-11	The Scripps Research Institute	Novel compounds as jnk kinase inhibitors
US9734210B2 (en)	2014-07-31	2017-08-15	Linkedin Corporation	Personalized search based on searcher interest
CZ201589A3 (cs) *	2015-02-11	2016-08-24	Zentiva, K.S.	Pevné formy soli Palbociclibu
UA124804C2 (uk) *	2016-08-15	2021-11-24	Пфайзер Інк.	Піридопіримідинонові інгібітори cdk2/4/6

2017
- 2017-07-31 UA UAA201900905A patent/UA124804C2/uk unknown
- 2017-07-31 CR CR20190062A patent/CR20190062A/es unknown
- 2017-07-31 PE PE2019000359A patent/PE20190475A1/es unknown
- 2017-07-31 AU AU2017311645A patent/AU2017311645B2/en active Active
- 2017-07-31 EP EP17752493.1A patent/EP3497103B1/en active Active
- 2017-07-31 GE GEAP201714998A patent/GEP20217234B/en unknown
- 2017-07-31 WO PCT/IB2017/054655 patent/WO2018033815A1/en active Application Filing
- 2017-07-31 SI SI201730793T patent/SI3497103T1/sl unknown
- 2017-07-31 US US15/664,265 patent/US10233188B2/en active Active
- 2017-07-31 PL PL17752493T patent/PL3497103T3/pl unknown
- 2017-07-31 DK DK17752493.1T patent/DK3497103T3/da active
- 2017-07-31 LT LTEP17752493.1T patent/LT3497103T/lt unknown
- 2017-07-31 KR KR1020197007466A patent/KR102236605B1/ko active IP Right Grant
- 2017-07-31 RS RS20210691A patent/RS61934B1/sr unknown
- 2017-07-31 MX MX2019001849A patent/MX2019001849A/es unknown
- 2017-07-31 TN TNP/2019/000039A patent/TN2019000039A1/en unknown
- 2017-07-31 CN CN202210092651.2A patent/CN114394966A/zh active Pending
- 2017-07-31 BR BR112019002610A patent/BR112019002610A2/pt active Search and Examination
- 2017-07-31 CA CA2975033A patent/CA2975033C/en active Active
- 2017-07-31 JP JP2019507917A patent/JP6563623B1/ja active Active
- 2017-07-31 ES ES17752493T patent/ES2876411T3/es active Active
- 2017-07-31 MA MA45920A patent/MA45920B1/fr unknown
- 2017-07-31 CU CU2019000010A patent/CU24522B1/es unknown
- 2017-07-31 CN CN201780063655.5A patent/CN109803968A/zh active Pending
- 2017-07-31 MD MDE20190682T patent/MD3497103T2/ro unknown
- 2017-07-31 SG SG11201900799XA patent/SG11201900799XA/en unknown
- 2017-07-31 RU RU2019104087A patent/RU2726115C1/ru active
- 2017-07-31 PT PT177524931T patent/PT3497103T/pt unknown
- 2017-07-31 HU HUE17752493A patent/HUE055978T2/hu unknown
- 2017-08-02 TW TW106126113A patent/TWI663169B/zh active
- 2017-08-04 UY UY0001037352A patent/UY37352A/es not_active Application Discontinuation
2019
- 2019-01-17 US US16/251,032 patent/US10800783B2/en active Active
- 2019-02-04 ZA ZA2019/00716A patent/ZA201900716B/en unknown
- 2019-02-06 IL IL264687A patent/IL264687B/en active IP Right Grant
- 2019-02-11 NI NI201900013A patent/NI201900013A/es unknown
- 2019-02-12 CO CONC2019/0001240A patent/CO2019001240A2/es unknown
- 2019-02-12 CL CL2019000368A patent/CL2019000368A1/es unknown
- 2019-02-14 DO DO2019000030A patent/DOP2019000030A/es unknown
- 2019-02-14 EC ECSENADI201911216A patent/ECSP19011216A/es unknown
- 2019-02-15 PH PH12019500329A patent/PH12019500329A1/en unknown
- 2019-02-15 SV SV2019005836A patent/SV2019005836A/es unknown
2020
- 2020-08-27 US US17/005,233 patent/US11396512B2/en active Active
2021
- 2021-06-01 HR HRP20210871TT patent/HRP20210871T1/hr unknown
- 2021-06-07 CY CY20211100495T patent/CY1124206T1/el unknown
2022
- 2022-06-15 US US17/841,138 patent/US20220324872A1/en active Pending

Also Published As

Publication number	Publication date
KR20190038915A (ko)	2019-04-09
KR102236605B1 (ko)	2021-04-05
ES2876411T3 (es)	2021-11-12
US11396512B2 (en)	2022-07-26
SI3497103T1 (sl)	2021-07-30
TW201819383A (zh)	2018-06-01
BR112019002610A2 (pt)	2019-07-02
CO2019001240A2 (es)	2019-02-19
US20190135817A1 (en)	2019-05-09
MA45920A (fr)	2019-06-19
CY1124206T1 (el)	2022-05-27
RS61934B1 (sr)	2021-07-30
PL3497103T3 (pl)	2021-10-25
MX2019001849A (es)	2019-05-09
RU2726115C1 (ru)	2020-07-09
HRP20210871T1 (hr)	2021-07-09
WO2018033815A1 (en)	2018-02-22
ZA201900716B (en)	2022-03-30
JP2019527722A (ja)	2019-10-03
CU24522B1 (es)	2021-06-08
TN2019000039A1 (en)	2020-07-15
DOP2019000030A (es)	2019-06-30
US20180044344A1 (en)	2018-02-15
UA124804C2 (uk)	2021-11-24
LT3497103T (lt)	2021-07-26
CA2975033C (en)	2023-01-24
AU2017311645A1 (en)	2019-02-28
CL2019000368A1 (es)	2019-05-10
ECSP19011216A (es)	2019-03-29
SV2019005836A (es)	2019-03-19
CU20190010A7 (es)	2019-10-04
TWI663169B (zh)	2019-06-21
NI201900013A (es)	2019-04-08
HUE055978T2 (hu)	2022-01-28
CN114394966A (zh)	2022-04-26
CN109803968A (zh)	2019-05-24
US20220324872A1 (en)	2022-10-13
UY37352A (es)	2018-03-23
EP3497103B1 (en)	2021-05-05
AU2017311645B2 (en)	2021-05-27
MA45920B1 (fr)	2021-08-31
IL264687B (en)	2021-04-29
CA2975033A1 (en)	2018-02-15
SG11201900799XA (en)	2019-02-27
US10800783B2 (en)	2020-10-13
JP6563623B1 (ja)	2019-08-21
US20200392142A1 (en)	2020-12-17
GEP20217234B (en)	2021-03-25
PE20190475A1 (es)	2019-04-04
CR20190062A (es)	2019-05-22
EP3497103A1 (en)	2019-06-19
US10233188B2 (en)	2019-03-19
PT3497103T (pt)	2021-06-17
MD3497103T2 (ro)	2021-08-31
PH12019500329A1 (en)	2019-10-28

Publication	Publication Date	Title
DK3497103T3 (da)	2021-06-14	Pyridopyrimdinon-cdk2/4/6-inhibitorer
DK3442972T3 (da)	2020-04-27	Bromdomænehæmmere
CU20160125A7 (es)	2017-01-10	Inhibidores de diacilglicerol aciltransferasa 2
DK3436823T3 (da)	2021-04-26	Antigen-array
DK3571192T3 (da)	2023-02-06	Jak1-selektive inhibitorer
DK3445708T3 (da)	2021-06-07	Stigbøjle
DK3335532T3 (da)	2019-10-14	Tandharve
DK3402792T3 (da)	2021-11-15	Quinolin-2-on-derivater
DK3630744T3 (da)	2023-03-06	Pyrazol-magl-inhibitorer
DK3509963T3 (da)	2021-10-11	Pallecontainer
MA46280A (fr)	2019-07-31	Inhibiteurs de la dopamine-b-hydroxylase
MA49006A (fr)	2020-02-05	Inhibiteurs d'ip6k
DK3528829T3 (da)	2022-05-30	Bacitracin-alginat-oligomer-konjugater
DK3575238T3 (da)	2022-01-31	Pallecontainer
MA46889A (fr)	2019-10-02	Inhibiteurs de gsk-3
DK3481826T3 (da)	2022-01-10	Tyrosinkinaseinhibitorer
DE112017006386A5 (de)	2019-08-29	Schraubarbeitszylinder
MA44607A (fr)	2021-05-19	Inhibiteurs de kinase
DE112017000734A5 (de)	2018-11-15	Glycolsensor
DK3471535T3 (da)	2021-06-28	Dyrelift
DK3237407T3 (da)	2020-07-20	3,5-diaminopyrazolkinasehæmmere
DK3710457T3 (da)	2022-10-24	Immunproteasomhæmmere
MA46888A (fr)	2021-06-02	Inhibiteurs de gsk-3
DK3323708T3 (da)	2019-06-24	Bovfender
DK3452590T3 (da)	2022-01-24	Plademagnet